Longevity Pulse
Academic PapersReviewsVideosPodcastsPress ReleasesClinical TrialsDrug ApprovalsTutorialsAnimations
All Articles
TutorialsClinical TutorialsVideosContinuous Listen
Free Subscription
Sign In
Deep Dive Audio
Azetukalner Cuts Seizures Up to 53% in Drug-Resistant Focal Epilepsy in Phase 3 TrialBrain Health

Azetukalner Cuts Seizures Up to 53% in Drug-Resistant Focal Epilepsy in Phase 3 Trial

About half of people with epilepsy do not achieve long-term seizure freedom with their first medication. This phase 3 trial tested azetukalner, a new drug that opens potassium channels to calm overactive brain cells. It enrolled 374 adults who were still having at least 4 focal seizures a month on 1 to 3 other medications. Over 12 weeks, median seizure frequency fell 10% on placebo, 35% on 15 mg and 53% on 25 mg. More than half of those on 25 mg had at least a 50% drop in seizures, versus about 1 in 5 on placebo. Dizziness, sleepiness, tremor and confusion were the main side effects, and they were more frequent at the higher dose. About 15% of those on 25 mg stopped the drug because of side effects. No deaths occurred.

0:00--:--
Read Full Article
Longevity Pulse

Developed by the Clinical and Foundational Medicine Institute

AI-powered summaries of the world's best longevity research — from peer-reviewed journals to expert podcasts and YouTube deep-dives. Built for those who take their healthspan seriously.

info@LongevityToday.com

Categories

CancerHeart DiseaseAlzheimer'sParkinson'sDiabetesGut HealthNutritionStrength & FitnessSupplements & PeptidesStem CellsReversing AgingAuto-ImmunityAdvanced Therapies

Platform

  • All Articles
  • Membership Plans
  • Search
  • Newsletter

Newsletter

Weekly longevity research, summarized.

Enter your email to subscribe:

© 2026 Longevity Pulse. All rights reserved.

About UsPrivacy PolicyTerms of UseMedical Disclaimer

Content on Longevity Pulse is for informational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before making health decisions.